NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice
Claudia GuerreroiD, Marta Casal, Cristina Alierta, Eduardo MoreoiD, Miguel Araujo‐VocesiD, Santiago UrangaiD, Ana Belén GómeziD, Carlos Martı́niD, Nacho AguilóiD
Abstract
Lung metastases frequently arise from primary tumors, including bladder cancer, and represent a critical negative prognostic factor. Natural Killer (NK) cells have shown to play a vital role in controlling metastasis. Consequently, tumor cells have evolved specific mechanisms to evade NK cell-mediated immune surveillance, promoting metastasis and resistance to immunotherapy. In this study, we investigated the prophylactic and therapeutic potential of intravenous Bacillus Calmette-Guerin (BCG) in preventing lung metastases from bladder cancer cells using a murine model. We demonstrated that prophylactic BCG administration significantly reduced tumor burden and prolonged survival, largely through NK cell activation. However, BCG treatment was ineffective when administered over established tumors, likely due to tumor-driven immune evasion mechanisms. Our results revealed the contribution of interferon-gamma (IFN-{gamma}) to tumor resistance. Tumor cells exposed to IFN-{gamma} upregulated were more resistant to BCG in vivo, which correlated with the overexpression of immune checkpoint molecules, whereas disruption of the IFN-{gamma} signaling pathway in tumor cells partially restored the therapeutic efficacy of BCG. Our findings highlight the importance of understanding tumor immune escape mechanisms and suggest that BCG could be a promising treatment for preventing lung metastases in bladder cancer.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.34
- Field percentile
- top 46%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Elevated HLA-E and NKG2A as a consequence of chronic immune activation defines resistance to M. bovis BCG immunotherapy in Non-Muscle-Invasive Bladder Cancer
D. Ranti, Y.-S. Wang, … A. Horowitz·bioRxiv·Mar 6, 2022
- BCG-induced reprogramming of monocyte/macrophage populations enhances lung antitumor immunity in mice
Eduardo Moreo, Miguel Araujo‐Voces, … Nacho Aguiló·bioRxiv·Jul 25, 2025
- The HLA-E/NKG2A axis identifies a therapeutic vulnerability in BCG-unresponsive bladder cancer
Bérengère Salomé, Haocheng Yu, … Amir Horowitz·bioRxiv·Sep 2, 2024
- Natural killer activation for bladder cancer elimination can be achieved in vitro by heat-killed BCG
G. Esteso, N. Aguilo, … M. Vales-Gomez·bioRxiv·Jun 4, 2020
- Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
J. H. van Puffelen, B. Novakovic, … S. H. Vermeulen·bioRxiv·Feb 21, 2022
- Macrophages drive the earliest anti-tumoral response to BCG therapy by directly killing bladder cancer through TNF signaling
M. Martinez-Lopez, C. R. de Almeida, … R. Fior·bioRxiv·Jan 5, 2024